Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus SABR for metastatic castration-resistant prostate cancer
ACTRN12618000954224Phase 2Recruiting
- Sponsor
- Monash Health
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Monash Health. Primary endpoint: Radiographic progression-free survival at 24 weeks. Started Dec 2017; status: recruiting.
02
Drugs
avelumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ACTRN12618000954224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000954224.